General
Preferred name
SOTRASTAURIN
Synonyms
AEB071 ()
AEB071, AEB-071, Sotrastaurin Acetate, NVP-AEB071 ()
Sotrastaurin (AEB071) ()
SOTRASTAURIN ACETATE ()
AEB-071 ()
NVP-AEB071 ()
Sotrastaurine ()
Sotrastaurina ()
P&D ID
PD003283
CAS
425637-18-9
949935-06-2
1058706-31-2
908351-31-5
Tags
available
drug candidate
Drug indication
Renal transplantation
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The discovery of sotrastaurin is described in . The compound is a a potent and selective pan-PKC inhibitor. (GtoPdb)
DESCRIPTION inhibitor of protein kinase C beta (Informer Set)
DESCRIPTION Sotrastaurin, also known as AEB-701, is an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively. Both PKCs are important in the activation of nuclear factor-kappaB (NF-kB). Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes. (BOC Sciences Bioactive Compounds)
Cell lines
3
Organisms
1
Compound Sets
29
AdooQ Bioactive Compound Library
A11554
Axon Medchem Screening Library
1635
BOC Sciences Bioactive Compounds
sotrastaurin-cas-425637-18-9-item-84-431417
Cayman Chemical Bioactives
16726
ChEMBL Drugs
CHEMBL565612
CHEMBL2105655
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
7946
Concise Guide to Pharmacology 2019/20
7946
Concise Guide to Pharmacology 2021/22
7946
Concise Guide to Pharmacology 2023/24
7946
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB12369
DrugMAP
DME53YS
EU-OPENSCREEN Bioactive Compound Library
EOS101288
Guide to Pharmacology
7946
Informer Set
661032
JUMP-Target 1 Compound Set
10296883
Kinase Inhibitors (best-in-class)
LINCS compound set
10408-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL565612
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL565612
MedChem Express Bioactive Compound Library
HY-10343
Novartis Chemogenetic Library (NIBR MoA Box)
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
sotrastaurin-aeb071
TargetMol Bioactive Compound Library
T6278
ZINC Tool Compounds
ZINC000003973984
External IDs
39
Properties
(calculated by RDKit )
Molecular Weight
438.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
6
Aromatic Ring Count
4
cLogP
2.43
TPSA
94.22
Fraction CSP3
0.2
Chiral centers
0.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PRKCB
PKC
PKC??
PKC??1
PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ
PRKCE
MARCKS
Compound status
clinical
Kinase group
AGC
Targets
PRKCQ
Pathway
Cytoskeletal Signaling
cytoskeleton
Epigenetics
TGF-beta/Smad
Member status
virtual
MOA
Protein Kinase PKC beta Inhibitors
Protein Kinase PKC theta Inhibitors
Protein Kinase PKC delta Inhibitors
Protein Kinase PKC alpha Inhibitors
Protein Kinase PKC epsilon Inhibitors
PKC inhibitor
Source data